The estimated Net Worth of Robin Swartz is at least $1.03 millió dollars as of 2 April 2024. Ms Swartz owns over 1,357 units of Voyager Therapeutics Inc stock worth over $734,785 and over the last 3 years she sold VYGR stock worth over $296,141.
Ms has made over 9 trades of the Voyager Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 1,357 units of VYGR stock worth $13,407 on 2 April 2024.
The largest trade she's ever made was selling 15,373 units of Voyager Therapeutics Inc stock on 15 March 2023 worth over $126,059. On average, Ms trades about 3,023 units every 62 days since 2022. As of 2 April 2024 she still owns at least 117,004 units of Voyager Therapeutics Inc stock.
You can see the complete history of Ms Swartz stock trades at the bottom of the page.
Robin Swartz is the Chief Operating Officer at Voyager Therapeutics Inc.
Ms Swartz is 50, she's been the Chief Operating Officer of Voyager Therapeutics Inc since . There are 10 older and 4 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
Robin's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 és Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: